Category: Stent Wars
A German court issues a 2nd injunction barring Boston Scientific from importing drug-eluting stents into that country.
OrbusNeich exercises its legal win by blocking the import of Boston Scientific's Promus, Taxus, Omega and Synergy stents into Germany.
OrbusNeich Medical wasted no time in enforcing a patent win against Boston Scientific (NYSE:BSX), announcing that it is blocking German imports of its rival's cardiac stents.
A German court grants a preliminary injunction against Boston Scientific in a legal row with OrbusNeich Medical over a pair of stent patents.
UPDATED April 30, 2013 with analyst's reaction; comment from Boston Scientific.
OrbusNeich Medical said a German court granted a preliminary injunction against Boston Scientific (NYSE:BSX) in a legal war over coronary stent patents.
A federal appeals court reverses a $593 million patent infringement loss for Johnson & Johnson's Cordis stent-making arm.
Johnson & Johnson (NYSE:JNJ) logged a major win for its Cordis stent-making arm today when a federal appeals court overturned a lower court decision to award more than $593 million to stent pioneer Dr. Bruce Saffran for patent infringement.
Saffran alleged that Cordis violated his patent with the Cypher drug-eluting stent, leading to a jury trial that went Saffran's way.
A federal appeals court upholds a lower court's decision to quash a pair of subpoenas sought by Johnson & Johnson's stent-making arm, Cordis Corp., which sought proof of its claims that Abbott copied stent patents.
Abbott (NYSE:ABT) held on to a win in its patent infringement war with Johnson & Johnson's (NYSE:JNJ) Cordis Corp. after a federal appeals court upheld a lower court ruling last month.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Abbott accuses Boston Scientific of poaching 1 of its stent sales vice presidents and 3 sales reps in an ongoing campaign aimed at "crushing" Abbott's stent operation.
